🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ANI Pharmaceuticals, Inc. ANIP R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.anipharmaceuticals.com
Company Profile ↓
$80.55
+23.56% 1Y
Mkt Cap$1.83B
P/E20.60
P/B3.10
52W High$98.81
52W Low$63.35
Book Value$26.34
EPS (TTM)$3.91

Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 87.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 40.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 20.6, below the sector median of 25.4.

Healthy Margins

Operating margin of 16.3% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $883.37M (+43.8% YoY); net profit $78.34M.
  • Trailing 12 Months Year-on-year growth — revenue +20.5%, earnings +86.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 40.8%, profit CAGR 87.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:40.81%
1 Year:20.50%

Compounded Profit Growth

5 Years:87.85%
1 Year:86.10%

Stock Price Performance

1 Year:+23.56%
6 Months:+5.60%
3 Months:+2.86%
1 Month:-1.35%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 49% of range
$63.35 $98.81
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)43.87 · Neutral
Price Performance
1M-1.35%
3M+2.86%
6M+5.60%
1Y+23.56%
Valuation vs Sector

P/E of 20.60 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 40.8% over 5 years.
  • Profit CAGR of 87.9% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.60
Industry PE
25.41
Forward P/E
7.53
PEG Ratio
-
Book Value
$26.34
Price to Book
3.10
P/S
2.01
EV/EBITDA
10.32
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
40.81%
Profit 5Y
87.85%
Revenue (YoY)
20.50%
Earnings (YoY)
86.10%

Profitability & Returns

ROCE
9.97%
ROE
18.32%
ROA
4.97%
Profit Margin
9.98%
Op Margin
16.30%
Gross Margin
60.83%
EPS (Latest Qtr)
$1.28
EPS (TTM)
$3.91

Balance Sheet & Liquidity

Debt/Equity
1.12
Quick Ratio
2.43
Current Ratio
3.12
Debt
$630.21M
Total Assets
$1.42B
Current Assets
$747.08M
Working Capital
$475.00M

Ownership

Promoter Holding
5.55%
Chg in Prom Hold
-0.01%
FII / Inst Holding
110.32%
Chg in FII Hold
-0.04%

Financial Snapshot

Enterprise Value
$1.83B
Total Revenue (TTM)
$923.71M
EBITDA
$197.38M
Free Cash Flow
$140.26M
Operating Cash Flow
$208.61M
Shares Outstanding
22.73M
Gross Margin
60.83%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANIP ANI Pharmaceuticals, Inc. R2K 80.55 20.60 $1.83B 0.00% 9.97% 18.32% 40.81% 87.85%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------36.63M44.76M48.16M-46.48M47.27M50.70M-52.89M54.36M51.34M47.97M49.77M48.47M52.98M57.25M54.52M48.62M52.06M64.48M73.86M83.82M106.79M116.55M131.83M137.43M138.04M--197.12M211.37M227.81M247.06M237.46M
Cost of Revenue -----------------------------------73.04M74.61M93.39M100.27M93.58M
Gross Profit -----------------------------------124.08M136.76M134.42M146.79M143.88M
Operating Expenses -----------------------------------109.98M121.59M111.59M117.66M105.17M
Operating Income 8.45M6.27M5.67M5.19M7.92M1.30M4.62M6.99M9.33M7.38M6.54M7.26M10.11M11.45M4.40M9.29M7.33M-4.67M-7.84M-11.31M2.80M331.00K3.04M-15.55M-3.56M-19.20M-12.91M-5.00M9.89M12.40M17.95M20.31M5.17M--14.10M15.17M22.83M29.13M38.71M
EBITDA -----------------------------------48.36M39.24M61.16M58.50M64.91M
Interest Expense -----------------------------------5.48M5.44M4.73M4.41M3.77M
Pretax Income -----------------------------------19.99M10.53M33.80M31.48M40.22M
Tax Provision -----------------------------------4.31M1.98M7.18M3.99M10.73M
Net Income 4.56M-1.35M1.12M2.54M-1.15M2.68M4.72M-2.25M2.78M5.04M-449.00K6.58M3.90M-4.83M-7.01M-12.34M434.00K-3.63M86.00K-14.11M-4.45M-20.13M-14.92M-8.60M1.44M6.25M9.94M18.21M-2.29M--15.68M8.55M26.62M27.49M29.49M
Diluted EPS 0.390.250.120.100.22-0.090.100.230.40-0.830.190.230.420.460.040.530.32-0.41-0.59-1.030.04-0.300.01-1.17-0.37-1.27-0.94-0.550.060.290.450.82-0.14--0.690.361.131.181.28
R&D Expense 815.00K-966.00K764.00K1.04M-1.62M2.17M2.63M-2.10M5.14M4.67M-4.37M5.77M4.98M-6.34M3.04M2.94M-2.97M2.81M2.46M5.27M4.17M7.66M5.92M7.37M11.12M10.51M7.30M10.13M-10.56M16.54M12.30M-10.60M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.26M2.47M435.16K20.37M30.08M55.97M76.32M128.62M176.84M201.58M206.55M208.47M-316.38M486.82M614.38M883.37M
Cost of Revenue -------------138.78M181.51M250.21M341.31M
Gross Profit -------------177.60M305.30M364.17M542.06M
Operating Expenses -------------203.33M255.77M361.95M460.83M
Operating Income ----42.00K898.00K20.01M32.70M20.08M28.33M35.36M16.35M-16.02M--25.73M49.53M2.22M81.23M
EBITDA -------------25.04M106.60M63.12M207.27M
Interest Expense -------------28.05M26.94M17.60M20.06M
Pretax Income --------------62.66M19.87M-22.21M95.79M
Tax Provision --------------14.77M1.09M-3.69M17.45M
Net Income -47.53M-46.20M-51.61M-1.51M301.00K28.75M15.38M3.93M-1.08M15.49M6.09M-22.55M--47.90M18.78M-18.52M78.34M
Diluted EPS -1.40-4.21-3.15-1.27-0.922.591.320.34-0.091.300.50-1.88--3.050.85-1.043.32
R&D Expense 13.68M39.71M44.18M1.16M1.71M2.68M2.87M2.91M9.07M15.39M19.81M16.00M11.37M22.32M34.29M44.58M51.66M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --44.77M62.38M13.75M44.50M259.56M285.26M322.86M412.14M430.60M456.79M461.19M-760.09M904.42M1.28B1.44B
Current Assets --------------344.26M519.82M528.46M753.12M
Cash & Equivalents 11.76M29.86M38.16M011.00K11.11M169.04M154.68M27.36M31.14M43.01M62.33M7.86M-48.23M221.12M144.86M285.58M
Inventory --------------105.36M111.20M136.78M143.07M
Receivables --------------165.44M162.08M221.73M281.08M
Total Liabilities --25.62M24.56M10.59M3.54M119.77M125.18M153.22M237.38M233.34M244.00M265.49M-421.55M446.82M855.94M899.65M
Current Liabilities --8.18M7.23M7.71M3.54M13.23M11.76M31.95M39.23M165.55M61.68M78.56M-99.44M145.48M194.45M278.11M
Long Term Debt ------106.54M113.43M069.95M67.30M175.81M172.44M-285.67M284.82M614.92M599.77M
Total Debt --------------286.52M285.67M624.09M617.03M
Total Equity 13.83M15.83M19.15M-34.28M-42.72M40.96M139.78M160.08M169.65M174.76M197.26M212.79M195.70M-338.54M457.60M428.53M540.72M
Shares Outstanding --------------17.64M20.73M21.54M23.11M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----137.00K-5.48M22.03M17.26M27.47M39.42M67.07M45.63M15.27M--31.20M118.96M64.02M185.22M
Investing Cash Flow ------35.75M-32.68M-149.06M-107.99M-27.38M-27.55M-68.32M--15.74M-18.51M-404.72M-34.32M
Financing Cash Flow ---440.00K-3.69M171.65M1.07M-729.00K72.36M-27.82M1.25M-1.44M--5.13M67.44M264.94M-9.94M
Capital Expenditure -165.72K-63.44K-719.92K-292.00K-191.00K-1.12M-2.18M-4.57M-10.37M-5.74M-6.63M-6.13M--16.45M-18.51M-16.95M-34.32M
Free Cash Flow ----429.00K-5.67M20.91M15.08M22.91M29.05M61.33M39.00M9.13M--47.66M100.45M47.06M150.90M
Net Change in Cash --------------52.07M167.89M-75.76M140.96M
Share Buybacks ---0433.00K002.50M001.03M1.52M890.00K1.96M4.99M10.96M12.21M
Dividends Paid ----------00190.00K1.62M1.62M1.62M1.16M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------56.1%62.7%59.3%61.4%
Operating Margin % ----0.2%3.0%35.7%42.8%15.6%16.0%17.5%7.9%-7.7%--8.1%10.2%0.4%9.2%
Net Margin % -3,777.9%-1,867.1%-11,859.7%-7.4%1.0%51.4%20.1%3.1%-0.6%7.7%3.0%-10.8%--15.1%3.9%-3.0%8.9%
ROE % -300.2%-241.3%150.5%3.5%0.7%20.6%9.6%2.3%-0.6%7.9%2.9%-11.5%--14.1%4.1%-4.3%14.5%
ROCE % ----0.7%2.2%8.1%12.0%6.9%7.6%13.3%4.1%-4.2%--3.9%6.5%0.2%7.0%

Shareholding Pattern

Insiders
5.55%
Institutions
110.32%
Public Float
116.80%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.09% 2.75M $236.97M
2 Vanguard Capital Management LLC 3.62% 823.06K $70.99M
3 Soleus Capital Management, L.P. 3.61% 820.24K $70.75M
4 State Street Corporation 3.39% 771.59K $66.55M
5 Tang Capital Management, LLC 3.11% 707.50K $61.02M
6 Goldentree Asset Management LP 2.94% 667.98K $57.61M
7 Deep Track Capital, Lp 2.64% 600.00K $51.75M
8 Millennium Management Llc 2.60% 592.01K $51.06M
9 Arrowstreet Capital, Limited Partnership 2.48% 564.36K $48.68M
10 Dimensional Fund Advisors LP 2.34% 531.19K $45.82M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANIP

Yahoo Finance Mon, 13 Jul 2026

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported were consistent with prior trials of fl…

Yahoo Finance Mon, 13 Jul 2026

ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run

Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares.

Yahoo Finance Fri, 10 Jul 2026

2 Value Stocks for Long-Term Investors and 1 We Avoid

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidd…

Yahoo Finance hu, 09 Jul 2026

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge

This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.

Yahoo Finance Mon, 06 Jul 2026

3 of Wall Street’s Favorite Stocks to Target This Week

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek …

Yahoo Finance Fri, 19 Jun 2026

How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?

Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.

ANIP — Frequently Asked Questions

What is the current share price of ANI Pharmaceuticals, Inc. (ANIP)?

As of 2026-07-14 21:23 PDT, ANI Pharmaceuticals, Inc. (ANIP) trades at $80.55 on NasdaqGM. Its 52-week range is $63.35 to $98.81.

What is the market capitalisation of ANIP?

ANI Pharmaceuticals, Inc. (ANIP) has a market capitalisation of $1.83B on NasdaqGM.

What is the P/E ratio of ANIP?

ANIP trades at a trailing price-to-earnings (P/E) ratio of 20.60. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.10.

What is the return on equity (ROE) of ANIP?

ANIP has a return on equity (ROE) of 18.32%. Its return on capital employed (ROCE) is 9.97%.

Is ANIP a good stock to buy?

This page provides a data-driven analysis of ANI Pharmaceuticals, Inc. (ANIP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space